OncoNet Rhein-Main e. V.

OncoNet Rhein-Main and Molecular Health cooperate to offer optimal therapy decisions for cancer patients

The OncoNet Rhein-Main is a network of clinics, molecular pathology laboratories, practices and medical centers that aims to provide effective and targeted care to all cancer patients in the Rhein-Main area. Working together, partners in the network support clinical studies to integrate innovative therapy approaches into daily clinical practice.

“We are very pleased about our collaboration with Molecular Health. We are united by the common goal of providing optimal treatment to people with cancer. With MH Guide, we have a digital tool for interdisciplinary case discussions in our tumor board. The interactive platform lets us correctly identify the steadily growing number of known genetic alterations in tumors to make the best possible treatment decisions.”

Prof. Dr. Christian Jackisch,
OncoNet Rhein-Main board member; chief physician at Sana Klinikum Offenbach

The OncoNet Rhein-Main network strives to offer cancer patients access to novel therapies via ongoing clinical studies. Matching patients and studies is challenging due to the increasing complexity and continually evolving landscape of molecular data in oncology.

As a regionally networked partner of the Rhein-Main area, Molecular Health supports therapy decisions by clinicians and pathologists with the structured processing and interpretation of next-generations sequencing (NGS) tumor profiles. Partners of OncoNet Rhein- Main receive onsite training to incorporate MH Guide into their translation of molecular data into practicable treatment decisions.

Patient benefit
The coverage in MH Guide of latest research findings, treatment recommendations, and ongoing clinical trials offer healthcare providers of the OncoNet Rhein-Main a rapid and accurate overview of approved and investigational therapy options. With detailed information about detected variants, all stakeholders can engage in multidisciplinary discussions to identify the best path for a patient based on a shared understanding of NGS data and, thus, offer patients individualized care.

Contact form

Charité Institute of Pathology

A long-standing collaboration between the Charité Institute of Pathology and Molecular Health enables interdisciplinary, pan-cancer therapy decisions in the molecular tumor board

The Institute of Pathology at the Charité Berlin is a key player in the care of cancer patients of the country’s capital and surrounding area. Their broad spectrum of analytical methods covers histological, cytological, and molecular diagnostics to deliver the reliable and timely identification of therapeutic options.

“We’ve been using MH Guide for several years in our laboratory and are very satisfied with its flexible application across the different tumor types, being processed and eva- luated in our laboratory.”

Prof. Dr. Michael Hummel,
Head of Molecular Pathology at the Institute of Pathology, Charité Berlin

To meet the rising demand in molecular analyses of a wide range of tumor types, the Institute of Pathology at the Charité Berlin looked to implement an effective and comprehensive solution for results interpretation of next-generation sequencing (NGS) data.

Molecular Health supports clinical routines in the Charité Institute of Pathology with the evaluation of NGS data from molecular analy- ses of various cancer types. The MH Guide software enables the rapid and transparent interpretation of molecular analyses, delivering patient-specific results in customized reports. MH Guide is used especially in the evaluation of large gene panels to perform the paral- lel analysis of multiple disease-relevant genes and the automated identification of diagnostic mutations.

Patient benefit
The long-standing collaboration between the Institute of Pathology at the Charité Berlin and Molecular Health grants patients access to personalized cancer treatment and to relevant clinical trials based on individual molecular tumor profiles. The partnership fosters the rapid, evidence-based interpretation of molecular diagnostic outcomes for all cancer types and thus, promotes effective discussions among the interdisciplinary members of the molecular tumor board.

Contact form

Gen Era Diagnostics

Gen Era Diagnostics and Molecular Health amplify and harmonize precision oncology in Turkey

Bildschirmfoto 2021-11-29 um 16.03.41
Gen Era Diagnostics is a leading provider of molecular diagnostics products and services in Turkey. The company has empowered scientists, clinicians, and laboratories in the investigation of diseases and the treatment of patients since 2013 with a comprehensive offering of cutting-edge research and diagnostic technologies.

“We are pleased to have Molecular Health on board in the near future as an experienced partner in precision medicine. With MH Guide, we can analyze and interpret molecular genetic data even faster and more comprehensively. This is an important addition to our service and product portfolio.”

Damla Bozkulak
Head of Marketing and Business Development at Gen Era Diagnostics

The rising demand for personalized treatment of cancer has forced oncologists and pathologists to grapple with a flood of data from genomic testing and a continually changing landscape of recommendations for therapies. Isolated interpretation of results from molecular tumor profiling can lead to unwanted disparities in patient care.

MH Guide supports the interpretation of cancer gene variants based on up-to-date clinical research and internationally recognized recommendations and guidelines. With a wide distribution to 20 laboratories, Gen Era facilitates the harmonized translation of genomic data into actionable treatment decisions.

Patient benefit
The collaboration between Molecular Health and Gen Era Diagnostics is a true example of how a game-changing product combined with the market reach of a visionary enabler can accelerate much needed improvements in cancer care. The use of MH Guide across multiple laboratories not only standardizes genomic data interpretation, but also streamlines the evaluation of individual cases by oncologists and molecular tumor boards. Both aspects make the promise of precision medicine a reality for more patients.

Contact form